China has issued a formal legal challenge to plans by Japan and the Philippines to negotiate a maritime boundary in waters east of Taiwan, arguing the talks constitute an "internationally wrongful act" because they bypass Beijing, which also claims rights in the area. A legal commentary and opinion released by the Ministry of Natural Resources’ China Institute for Marine Affairs say the two US allies are proceeding "without consultation with China" in a zone where the three countries’ exclusive economic zone and continental shelf claims overlap extensively.

The Chinese side argues that, given the "overall geographical situation and the relative positions of the relevant coasts," any delimitation of exclusive economic zones (EEZs) and continental shelves in the waters east of Taiwan inevitably involves China as well as Japan and the Philippines. Under the United Nations Convention on the Law of the Sea, all three are coastal states entitled to claim EEZs extending 200 nautical miles from their baselines. Beijing says those claims intersect in much of the area that Tokyo and Manila intend to address bilaterally, making a two-party negotiation inconsistent with obligations owed to a third claimant.

In the legal documents and public statements, Chinese agencies contend that the move violates principles of sovereign equality, good faith, cooperation and self-restraint under international law. The Ministry of Natural Resources commentary and the think tank opinion both state that the announcement "in disregard of the region's specific geographical circumstances" has harmed China’s maritime rights and interests. The Foreign Ministry has lodged what it calls solemn representations with Japan and the Philippines, and a spokeswoman for the State Council’s Taiwan Affairs Office described the proposed delimitation talks as "completely illegal, null and void."

Beijing also underscores that, as the "state whose rights and interests have been injured," it is "entitled to invoke the responsibility of Japan and the Philippines" over what it labels "internationally wrongful acts." It is calling on the two governments to halt their bilateral negotiations and instead enter into consultations with China. Relevant Chinese maritime authorities, including the China Coast Guard, have conducted patrols in waters east of Taiwan in recent days, which officials in Beijing describe as a lawful exercise of jurisdiction in areas where they say China’s EEZ and continental shelf claims overlap with those of its neighbors.

Indonesia menambah amunisi dalam menangani beban penyakit metabolik yang kian berat dengan kehadiran tirzepatide, terapi inovatif untuk diabetes melitus tipe 2 dan obesitas. PT Anugerah Pharmindo Lestari (APL), bagian dari Zuellig Pharma, resmi menghadirkan obat agonis reseptor ganda glucose-dependent insulinotropic polypeptide (GIP) dan glucagon-like peptide-1 (GLP-1) pertama di pasar domestik setelah memperoleh persetujuan dari Badan Pengawas Obat dan Makanan (BPOM). Langkah ini dinilai strategis di tengah meningkatnya prevalensi diabetes dan obesitas di Indonesia.

Data International Diabetes Federation (IDF) Diabetes Atlas 2025 menunjukkan sekitar 20,4 juta penduduk Indonesia berusia 20–79 tahun hidup dengan diabetes, dan angka ini diproyeksikan naik menjadi 28,6 juta pada 2050 jika tidak ada pengendalian efektif. Survei Kesehatan Indonesia (SKI) 2023 mencatat prevalensi obesitas dewasa sudah mencapai 23,4 persen, lebih tinggi dibandingkan satu dekade lalu. Kombinasi dua kondisi tersebut meningkatkan risiko komplikasi serius seperti penyakit kardiovaskular dan gangguan ginjal kronis, sekaligus menekan kualitas hidup pasien.

APL menyebut peluncuran tirzepatide dimungkinkan berkat skema percepatan yang diterapkan BPOM. Obat ini mendapatkan izin edar dalam 98 hari kerja, sementara persetujuan indikasi untuk manajemen berat badan kronis diselesaikan hanya dalam 42 hari kerja melalui mekanisme reliance. Kebijakan percepatan yang mulai berlaku 1 Agustus 2025 memungkinkan obat inovatif yang telah disetujui di negara referensi dan memiliki dokumen lengkap diproses sekitar 90 hari kerja, tanpa menurunkan standar keamanan, khasiat, dan mutu. Kepala BPOM Taruna Ikrar menegaskan setiap produk tetap melalui evaluasi ilmiah menyeluruh meski memperoleh jalur cepat.

Taruna menyoroti bahwa sebelumnya banyak obat inovatif hanya tersedia di luar negeri sehingga pada praktiknya lebih mudah diakses kelompok berpendapatan tinggi yang mampu berobat ke negara tetangga seperti Singapura. Dengan persetujuan tirzepatide di dalam negeri, regulator berharap kesenjangan akses dapat diperkecil. Secara mekanisme, tirzepatide bekerja mengaktivasi dua reseptor hormon GIP dan GLP-1 yang meniru kerja hormon alami tubuh, membantu meningkatkan kerja insulin, mempercepat masuknya glukosa ke dalam sel, serta mencegah penumpukan gula di pembuluh darah yang dapat memicu aterosklerosis dan komplikasi lain. Di tengah kenaikan tajam kasus diabetes dan obesitas, kehadiran terapi ini diposisikan sebagai perluasan pilihan tatalaksana berbasis bukti ilmiah bagi pasien dan tenaga kesehatan di Indonesia.